Primary B-Cell Analysis

How Our Technology Improves Primary B-Cell Analysis

Antibody-derived biologics have become a major class of therapeutic, particularly in the fight against cancer and autoimmune diseases. Recent developments in single cell gene sequencing and recombinant immunoglobulin expression have enabled direct screening of native B-cells (B-lymphocytes), giving the potential for much more of the mammalian immune system repertoire to be deep-mined.

Current techniques such as FACS are poor at analysing the antibody secreted from each cell. The process can be far more effectively streamlined through the use of our high-throughput picodroplet technology. Screen greater numbers of clones, in a shorter amount of time, and increase your chances of finding rare and valuable variants within your B-cell repertoire.

The Unique Benefits of Our Systems for Primary B-Cell Screening

Using our microfluidic technology for B-cell analysis involves animal immunisation and the subsequent isolation of B-cells. What’s the key difference? By using picodroplets to sort and screen individual cells you can automatically isolate the cells that are secreting the antigen-specific antibody for further analysis. Once these cells have been identified, they can be used for a number of applications, including further assays, RT-PCR of antibody transcripts, next generation sequencing and hybridoma generation.

Primary B cell analysis workflow

Our Systems in Action for Primary B-Cell Screening

We understand the importance of maintaining cell viability throughout the research process, particularly when working with sensitive cells. That’s why our technology has been tested to ensure that the viability of primary B-cells remains high when grown and analysed in picodroplets. As can be seen in the graph, cells housed in 300 pL picodroplets remain viable over the four hour incubation period that is standard for most of the workflows carried out using our systems. This viability is crucial in primary B-cell analysis, as the cells often need to be happy and healthy after screening and sorting, so they are ready for use in downstream applications.

Primary B cell viability over four hours